Insights

Phoenix Pharmacy Claims

Earnest Analytics
  • Healthcare
  • Pharmacy

GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
  • Healthcare
  • Pharmacy

GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
  • Healthcare
  • Pharmacy

GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes
  • Healthcare
  • Macro

Camzyos: early claims data trends pointing to strong therapy adherence
  • Healthcare
  • Pharmacy

Discontinuations damper Relyvrio’s launch
  • Healthcare
  • Pharmacy

Orladeyo: A Tough Pill to Swallow for Competitors in the HAE Space 
arrow-downarrow-leftarrow-rightcaret-down-menucaret-downcarrot-rightcheckclosefacebook-squarefilterhamburgerinstagram-squarelinkedin-squaremobile-parent-indicatorpauseplayprintertwitter-square